Liposomal
doxorubicin | Liposomal Vincristine | Resources
& Research News
Treatment
agents "can be encapsulated in long-circulating
Stealth liposomes. Liposomes are microscopic vesicles composed of a phospholipid bilayer that are capable of encapsulating active drugs. The Stealth liposomes are formulated with surfacebound methoxypolyethylene glycol, a process often referred to as pegylation, to protect liposomes from detection by the mononuclear phagocyte system and to increase blood
circulation time. It is hypothesized that liposomal drug molecules are able to penetrate the vasculature of tumours."
New developments:
-
Liposomal
antisense - Related
articles
-
Immunoliposomal
anticancer drugs:
Improved outcome when B-cell lymphoma is treated with
combinations of immunoliposomal
anticancer drugs targeted to both the CD19 and CD20 epitopes
(antigens).
Clin Cancer Res. 2004 Apr 1;10(7):2530-7. PMID:
15073133 | Related
Articles | Background
Recommended
Resources:
Liposomes are microscopic spherical vesicles that
form when phospholipids are hydrated.
Evaluation of Drug Targeting Strategies and
Liposomal Trafficking - bentham.org
-
Liposomal
doxorubicin (Doxil™, Caelyx®,
Myocet®)
Doxorubicin
(anthracyclines) can effectively treat aggressive and transformed
lymphoma. However, the use of this chemotherapy agent is limited
by its toxicity, particularly to the heart. A liposome encapsulated
form of the drug called Doxil appears to be safer, and early
indications are encouraging in respect to responses (see below), but
most experts believe that more clinical data and long-term
assessment of side effects are needed before it can be used
routinely as a frontline substitution for doxorubicin. [1]
Mechanism: "Pegylated-liposomal
doxorubicin (Doxil™) is a unique form of liposomal doxorubicin in
which the liposomes are coated with polyethylene glycol. The
polyethylene glycol confers useful properties including a diminished
uptake by the reticuloendothelial
system, leading to a much longer
half-life in blood (~50-60 hours), and a different toxicity profile
than non-pegylated liposomes. " - cancer.med.umich.edu
NOTE: "Avoid
hot showers or baths, steam baths or hot tubs 24 before and for 72
hours after treatment with liposomal doxorubicin. This may help
decrease the occurrence of certain skin reactions." - jasper-web.com
Resources:
-
Pegylated Liposomal Doxorubicin: Tolerability and Toxicity -
Medscape (free login req.) 02_01_03
-
-
Evaluation of Drug Targeting Strategies and
Liposomal Trafficking - bentham.org
-
-
Side effects - Cardiac - PAL
|
-
Side effect relief - Do's and Don'ts - cancerlynx.com
-
Full prescribing information from the sponsor - Pdf
Treatment-Related Abstracts:
-
Pegylated liposomal doxorubicin as single-agent
treatment of low-grade non-Hodgkin's lymphoma:
a phase II multicenter study. Clin Lymphoma. 2003 Mar;3(4):235-40.
PMID:
12672273 | Related
articles
-
Multicenter study of pegylated liposomal doxorubicin in patients
with cutaneous T-cell lymphoma.
Cancer. 2003 Sep 1;98(5):993-1001. PMID:
12942567
-
Pegylated liposomal doxorubicin in combination
chemotherapy in the treatment of previously
untreated aggressive
diffuse large-B-cell lymphoma.
Med Oncol. 2002;19(1):55-8. PMID: 12025891 - PubMed
-
Treatment of relapsing or recalcitrant cutaneous
T-cell lymphoma with pegylated liposomal doxorubicin.
J Am Acad
Dermatol. 2000 Jan;42(1 Pt 1):40-6.
PMID: 10607318 - PubMed
-
Cyclophosphamide, pegylated liposomal doxorubicin
(Caelyx"), vincristine and prednisone (CCOP)
in elderly
patients with diffuse large B-cell lymphoma: results from a
prospective phase II study.
Haematologica. 2002 Aug;87(8):822-7.
PMID: 12161358 - PubMed
-
Targeted delivery and triggered release of
liposomal doxorubicin enhances cytotoxicity against
human B
lymphoma cells. Biochim Biophys Acta. 2001 Dec 1;1515(2):144-58.
PMID: 11718670 - PubMed
-
LIPOSOMAL DOXORUBICIN: A phase I/II trial of liposomal
doxorubicin (TLC D-99, Myocet) with
cyclophosphamide, vincristine,
and prednisone in newly diagnosed aggressive NHL
Year: 2002 Abstract No: 1133
-
Liposomal encapsulated anthracyclines: new
therapeutic horizons.
Curr Oncol Rep. 2001 Mar;3(2):156-62. Review. PMID: 11177748 - PubMed
-
Liposomal Vincristine (ONCO-TCS™)
- ONCO-TCS - The TCS means transmembrane carrier
systems. It's a drug delivery system that uses a lipid
envelope to encapsulate intravenous chemotherapeutic drugs,
allowing them to circulate in the bloodstream for several hours
after injection and selectively accumulate at a disease site.
It's an investigational therapy being tested currently for
aggressive NHL. Sponsor describes
technology with animation here: INEX
-
Marqibo Not Eligible For Accelerated Approval, Committee Says
- fdaadvisorycommittee.com
"Inex/Enzon’s liposomal vincristine injection Marqibo
should not be eligible for accelerated approval since there are
other therapies for relapsed non-Hodgkin’s lymphoma, FDA’s
Oncologic Drugs Advisory Committee agreed Dec. 1."
-
Inex Pharmaceuticals
initiates submission of New Drug Application for Onco TCS to the
United States FDA - newswire.ca
Oct_03
-
Phase I study of
liposomal vincristine. J Clin Oncol. 1999 Feb;17(2):697-705. PMID:
10080616 - PubMed
| Related
abstracts
-
INEX
achieves positive pivotal Phase II/III clinical trial results to
seek FDA marketing approval for Onco TCS (liposomal vincristine)
for relapsed aggressive non-Hodgkin's lymphoma (NHL). - Newswire
Dec_03_02
-
Liposomal vincristine
in relapsed non-Hodgkin's lymphomas: early results of an ongoing
phase II trial.
Ann Oncol. 2000 Jan;11(1):69-72. PMID: 10690390 - PubMed
-
Onco
TCS: first-line treatment for the aggressive form of NHL Will it
replace the current standard, CHOP + Rituxan?
- INEX
11_07_2
-
Preclinical
pharmacology, toxicology and efficacy of sphingomyelin/cholesterol
liposomal vincristine for therapeutic treatment of cancer - springer-ny.com
Encapsulation of
vincristine in liposomes reduces its toxicity and improves its
anti-tumor efficacy. - liposomes.ubc.ca
-
LIPOSOMAL VINCRISTINE: A phase II study of liposomal
vincristine in CHOP with rituximab for elderly patients with
untreated aggressive B-cell non-Hodgkin's lymphoma (NHL). Year:
2002 Abstract No: 1132
|
